Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides. Its product candidate, ALRN-6924, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins MDMX and MDM2.